Merck Patent Gmbh

Merck Patent Gesellschaft MIT Beschrankter Haftung

Merck Patent Gesellschaft MIT Beschraenkter Haftung

Wolfgang Staehle

Kai Schiemann

Melanie Schultz

Christos Tsaklakidis

Alfred Jonczyk

Birgitta Leuthner

Dirk Wienke

Wilfried Rautenberg

Oliver Schadt

Guenter Hoelzemann

Hans-Peter Buchstaller

Simon Lawrence Goodman

Andree Blaukat

Frank Zenke

Christiane Amendt

Thomas Fuchss

Dirk Finsinger

Helene Crassier

Paul Czodrowski

David Bruge

Manja Friese-Hamim

Ingo Kober

Andreas Goutopoulos

Bayard R Huck

Hartmut Greiner

Nadia Brugger

Timo Heinrich

Srinivasa R Karra

Margarita Wucherer-Plietker

Ulrich Emde

Karl-August Ackermann

Mireille Krier

Christa Burger

Eike Staub

Ansgar Wegener

Francesc Mitjans

Jaume Adan

Oliver Poeschke

Michael Busch

Maria Kordowicz

Christine Knuehl

Elisabet Rosell-Vives

Brigitta Leuthner

Marta Soler Riera

Frank Czauderna

3-substituted cyclopentylamine derivatives

Compounds of the formula I in which R, X, X, X, X, R, Rand q have the meanings indicated in Claimare inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

Piperazine derivatives as FASN inhibitors

Compounds of the formula I in which R, W, R, R, X, X, X, Xand q have the meanings indicated in claimare inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

3-aminocyclopentane carboxamide derivatives

Compounds of the formula I in which R, Y, R, X, X, Xand q have the meanings indicated in claim, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

1,3-Disubstituted cyclopentane derivatives

Compounds of the formula I in which R, R, R, R, X, X, X, X, q and W have the meanings indicated in claimare inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

1,3-diaminocyclopentane carboxamide derivatives

The invention provides novel substituted benzyl piperidine compounds according to Formula (I) as lysophosphatidic acid (LPA) receptor antagonists, their manufacture and use for the treatment of proliferative or inflammatory diseases, such as cancer, fibrosis or arthritis.

Benzyl piperidine compounds as lysophosphatidic acid (LPA) receptor antagonist

The present invention relates to piperidine and pyrazine derivatives according to formulae (Ia), (Ib) and (II) as autotaxin inhibitors and the use of such compounds for the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by increased lysophosphatic acid levels and/or the activation of autotaxin, in particular of different cancers.

Piperidine and piperazine derivatives as autotaxin inhibitors

Compounds of the formula I in which R, R, R, X, X, X, X, n1, n2, n3 and n4 have the meanings indicated in claim are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. 

Hydropyrrolopyrrole derivatives for use as fatty acid synthase inhibitors

Pyrido-pyrimidine derivatives

Compounds of the formula I in which R, R, X and Y have the meanings indicated in Claim, are inhibitors of TBK1 and IKK&#x3b5; and can be employed, inter alia, for the treatment of cancer and inflammatory diseases.

Thiazole derivatives

The present invention relates to novel pyrazolopyridinone derivatives according to formula (I) and a process of manufacturing thereof. These pyrazolopyridinone derivatives can be used as LPA receptor antagonists for the treatment of various herein disclosed diseases.

Pyrazolopyridinone derivatives as LPA receptor antagonists

The present invention relates to benzonaphthyridinamines of the formula (I) as autotaxin inhibitors and to the use thereof in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions in which the inhibition, regulation and/or modulation of phosphodiesterase or lysophospholipase autotaxin plays a role, in particular of various types of cancer and autoimmune and inflammatory diseases.

Benzonaphthyridinamines as autotaxin inhibitors

The invention provides novel substituted cyclopropane carboxamide compounds according to Formula (I), their manufacture and use for the treatment of proliferative or inflammatory diseases, such as cancer, fibrosis or arthritis.

N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists

The invention relates to compounds of the formula (I), to the preparation and use thereof for the preparation of a medicament for the treatment of diseases, in particular tumors and/or diseases in the development or course of which kinases are involved. 

Azaheterocyclic compounds as kinase inhibitors

Growing community of inventors

Ingelheim, Germany

Wolfgang Staehle